Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25440357 | 0.80 | NPC1 (0.36) | RAB9ANPC1SMN1; SMN2ALDH1A1GRM2 | |
| SCHEMBL14332620 | 0.62 | ALDH1A1 (0.36) | NISCHRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5460700 | 0.61 | MEN1 (0.36) | NISCHRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| Biphenyl SCHEMBL11779109 | 0.58 | ALDH1A1 (0.90) | RAB9ANPC1SMN1; SMN2ALDH1A1NFKB1 | |
| Biphenyl SCHEMBL1627414 | 0.58 | ALDH1A1 (0.90) | RAB9ANPC1SMN1; SMN2ALDH1A1NFKB1 | |
| Biphenyl SCHEMBL28376025 | 0.58 | ALDH1A1 (0.60) | NISCHRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7541231 | 0.58 | — | — | |
| SCHEMBL20618802 | 0.58 | ALDH1A1 (0.46) | RAB9ANPC1ALDH1A1KDM4EMEN1 | |
| Biphenyl SCHEMBL1950563 | 0.58 | ALDH1A1 (0.50) | NISCHSMN1; SMN2ALDH1A1GRM2MEN1 | |
| Biphenyl SCHEMBL6740039 | 0.57 | ALDH1A1 (0.69) | SMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019477-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2021-05-26 | — | — | EP | disclosed |
| US-9714224-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-07-25 | — | — | US | disclosed |
| US-9714224-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-07-25 | — | — | US | disclosed |
| US-20160145213-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2016-05-26 | — | — | US | disclosed |
| US-20160145213-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145213-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | AGTR2, AGTR1, AGT | NISCH 2339/4885RAB9A 3785/4885NPC1 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.